企業概要
China SXT Pharmaceuticals, Inc. is a pharmaceutical enterprise dedicated to the research, development, manufacturing, marketing, and sale of traditional Chinese medicine pieces (TCMP) within the Chinese market. The company specializes in providing advanced, fine, and regular TCMP products alongside raw medicinal materials such as SanQiFen and HongQi, positioning itself within the broader healthcare ecosystem. This entity operates specifically in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, a classification that denotes its focus on producing specific therapeutic agents rather than generic commodities. The firm employs approximately 75 individuals to execute its operational strategy. In terms of market capitalization, the company is valued at $1.92M, while its trailing twelve-month revenue stands at $1.54M. These financial metrics collectively indicate that China SXT Pharmaceuticals, Inc. operates as a micro-cap entity with a very small revenue base relative to its industry peers. The combination of a sub-$2M market cap and limited annual revenue suggests the company occupies a niche position with minimal scale, reflecting its status as a small-cap player rather than an established large-cap pharmaceutical corporation.
財務健全性
The company reported a trailing twelve-month revenue of $1.54M, yet it simultaneously recorded a net income of $-8,869,886 and an EBITDA of $-8,335,278. The substantial disparity between the positive revenue figure of $1.54M and the negative net income reveals a highly inefficient cost structure where operating expenses and losses far exceed the top-line income. Furthermore, the free cash flow stands at $-1,948,357, indicating that the company is burning cash rather than generating liquidity, which significantly constrains its current financial flexibility and ability to fund operations without external financing. Profitability is further evidenced by the margins, where the gross margin is 21.7%, the operating margin is -1011.7%, and the profit margin is 0.0%. The gross margin indicates that the cost of goods sold consumes the majority of revenue, while the negative operating margin of -1011.7% signals that operating expenses are magnitudes higher than gross profit. The 0.0% profit margin confirms that the company is currently unprofitable on an accrual basis. On the balance sheet side, the company holds $21.31M in cash against $1.20M in debt, resulting in a debt-to-equity ratio of 5.95. Despite the high debt-to-equity ratio, the significant cash reserve suggests the balance sheet is not currently leveraged in a way that threatens solvency, though the high ratio indicates potential equity dilution risks. Liquidity is supported by a current ratio of 4.37, which indicates a strong ability to meet short-term obligations with its current assets. However, the return on equity is -50.3% and the return on assets is -18.3%, metrics that reveal that management is currently ineffective at generating value for shareholders or utilizing assets profitably.
バリュエーション評価
Both the trailing P/E ratio and the forward P/E ratio are listed as N/A due to the company's lack of earnings, a status that implies the market is pricing the stock based on assets or revenue rather than profitability expectations. The price-to-book ratio is 0.09, a figure that indicates the stock is trading at a significant discount relative to its book value, suggesting the market assigns little premium to the company's tangible assets. Alternative valuation metrics include a price-to-sales ratio of 1.25 and an EV/EBITDA of 2.20, which suggest the company is valued roughly equal to its sales revenue despite its lack of earnings power. The stock's price volatility is highlighted by a 52-week high of $1047.00 and a 52-week low of $1.25. Given the extreme spread between the high and low, the current price sits near the absolute bottom of this range, specifically trading at approximately 99.9% below the 52-week high. The beta value is 1.75, which means the stock is expected to be 75% more volatile than the broader market, reflecting high sensitivity to market movements and specific sector risks. This high beta combined with the lack of earnings makes the valuation highly speculative and dependent on non-financial catalysts or asset restructuring.
Growth & Income
The revenue growth year-over-year is -24.5%, while earnings growth is N/A due to the absence of positive earnings in the trailing period. The negative revenue growth indicates that the company's sales are contracting, which is a headwind to any potential future earnings recovery. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders, implying that any retained earnings are instead consumed by the significant operational losses rather than being reinvested into growth initiatives. Consequently, the overall growth and income profile is characterized by declining sales, a complete absence of profitability, and a lack of shareholder returns through dividends.